The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients
Abstract
Summary: Background: Non‐alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver injury. Currently, there are no proven effective therapies available. Atorvastatin is a new 3‐hydroxy‐3‐metylglutaryl coenzyme A reductase inhibitor that reduces lipid serum levels. Aim: To evaluate the effectiveness and safety of atorvastatin in dyslipemid, non‐alcoholic fatty liver patients. Patients and methods: We prospectively enrolled 25 patients with NAFLD; 22 of them completed the study. Body mass index, serum lipids, liver function tests and liver density assessed by echography were measured at baseline and after 1, 3, 6, 9 and 12 months of treatment. Normalization of transaminases and/or improvement in liver density were treatment end points. Patients received atorvastatin (10–80 mg/daily) according to basal serum choleresterol levels; additionally, they were given standard weight‐loss counselling and encouraged to follow a low fat diet. Results: All 22 patients (14 men, mean age 47 ± 10 years) had high cholesterol levels at baseline and 11 (44%) also presented high trygliceride levels. After 6 months of treatment, eight patients (36.3%) presented normal transaminase levels. The remaining patients continued treatment for 12 months when 20% of patients presented with normal transaminase levels, while the other patients showed a 10% reduction in basal levels. Mean cholesterol levels were 268.5 ± 44.2 and 186.8 ± 14.4 mg/dL before and after treatment, respectively (P < 0.05). The mean body mass index was 27.4 ± 3.1 at baseline and 26.3 ± 2.8 kg/cm 2 at the end of treatment (P > 0.05). No side effects were reported. Conclusions: Serum aminotransferase and lipid levels were reduced significantly in all patients with atorvastatin treatment. Therapy with atorvastatin in NAFLD patients with hyperlipidemia was found to be both effective and safe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Powell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473
(2004) · Seminars in Liver Disease · doi:10.1055/s-2004-823098 · Cited by 481
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.128 · Cited by 585
Non-alcoholic fatty liver disease and increased risk of cardiovascular disease
Targher, G., & Arcaro, G. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.021 · Cited by 551
Metadata
- Authors
- GÓMEZ‐DOMÍNGUEZ, E., GISBERT, J. P., MORENO‐MONTEAGUDO, J. A., GARCÍA‐BUEY, L., & MORENO‐OTERO, R.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-05-12
- Volume
- 23
- Issue
- 11
- Pages
- 1643-1647
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2009922326
- Cited by
- 189
- References
- 3
- FWCI
- 10.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients. https://app.cochat.ai/papers/10.1111/j.1365-2036.2006.02926.x
- The paper
- GÓMEZ‐DOMÍNGUEZ, E., GISBERT, J. P., MORENO‐MONTEAGUDO, J. A., GARCÍA‐BUEY, L., & MORENO‐OTERO, R. (2006). A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2006.02926.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.